Trial Profile
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Droxidopa (Primary)
- Indications Orthostatic hypotension
- Focus Therapeutic Use
- Acronyms RESTORE
- Sponsors Lundbeck A/S
- 23 Sep 2022 Status changed from active, no longer recruiting to completed.
- 28 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2022 Results (n=114) published in the Neurology and Therapy